Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care products and services to office-based dental and medical practitioners, announced today that its board of directors has authorized the repurchase of up to $750 million of shares of the company’s common stock.
This program is in addition to the $500 million repurchase program announced in January 2025, which is anticipated to be fully executed by the end of the first quarter of 2026.
The company had approximately 118.6 million shares outstanding as of September 8, 2025. This new authorization represents approximately 9.0 percent of shares outstanding at the current stock price. Purchases may be made from time to time in the open market or through negotiated transactions.
“Henry Schein’s decision to repurchase shares reflects the confidence we have in our 2025–2027 BOLD+1 strategic plan and its potential to deliver sustainable growth and value,” said Ronald N. South, senior vice president and chief financial officer. “With the support of a strong balance sheet, we are well positioned to serve our markets and further expand the depth and reach of our health care solutions.”
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes.
Our business, clinical, technology, and supply chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.
Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers.
A Fortune 500 company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 33 countries and territories. The company’s sales reached $12.7 billion in 2024 and have grown at a compound annual rate of approximately 11.2 percent since Henry Schein became a public company in 1995.
For more information, visit www.henryschein.com, facebook.com/HenrySchein, instagram.com/HenrySchein, linkedin.com/company/HenrySchein, and @HenrySchein on X.
Cautionary Note Regarding Forward-Looking Statements
In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations, and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, and achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.
These statements are generally identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to make,” or other comparable terms. A fuller discussion of our operations, financial condition, and status of litigation matters—including factors that may affect our business and future prospects—is contained in documents we have filed with the United States Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K, and will be contained in all subsequent periodic filings we make with the SEC.
These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.
Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to:
- Our dependence on third parties for the manufacture and supply of our products and raw materials
- Strategic growth risks, including restructuring and joint ventures
- Security risks related to technology products and cyberattacks
- Competitive pressures and market consolidation
- Changes in tax, regulatory, and healthcare legislation
- Global economic and political instability, including geopolitical conflicts
- Supply chain disruption and shipping cost increases
- Leadership transitions and workforce challenges
- Litigation, intellectual property risks, and activist investor activity
The order in which these factors appear should not be construed to indicate their relative importance or priority.
We caution that these factors may not be exhaustive and that many are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements except as required by law.
